Adarsh Mallepally
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adarsh Mallepally has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Nitin Chetla
University of Virginia School of Medicine, Charlottesville, VA, United States
5 shared publications - Botan Zebari
St. James School of Medicine, Binghamton, NY, United States
4 shared publications - John Chen
Albany Medical College, Albany, NY, United States
4 shared publications - Jonathan Silva
Albany Medical College, Albany, NY, United States
4 shared publications - Kunal Sukhija
Kaweah Health, Visalia, CA, United States
4 shared publications - Matthew Cullen
Albany Medical College, Albany, NY, United States
4 shared publications
Latest Publications
- 13 October 2026
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 134, 741-752
Anatomic Level as a Modifier of Racial/Ethnic Disparities in Chronic Limb-Threatening Ischemia: Outcomes after First-Time Endovascular Revascularization
- 13 October 2026
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 134, 741-752
Anatomic Level as a Modifier of Racial/Ethnic Disparities in Chronic Limb-Threatening Ischemia: Outcomes after First-Time Endovascular Revascularization
- 25 September 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Comparative Analysis of Systemic Complications of Antivascular Endothelial Growth Factor Therapies in Retinal Diseases
Purpose: To compare the systemic safety profiles of antivascular endothelial growth factor (anti-VEGF) agents using a large real-world dataset. Methods: The TriNetX Research Network database was used to identify adults with macular edema secondary to diabetes, retinal vein occlusion, or age-related macular degeneration who received bevacizumab, ranibizumab, or aflibercept (2012–2022) or faricimab (2022–2024). The bevacizumab cohort was matched with the other cohorts using propensity score matching to account for demographic characteristics and comorbidities. Outcomes included stroke, venous thromboembolism, myocardial infarction, hypertension, brain hemorrhage, and renal function. Results: In the propensity score–matched cohorts comparing outcomes between bevacizumab and aflibercept (each n = 9538), bevacizumab was associated with higher mean blood urea nitrogen level (28.07 mg/dL vs 26.89 mg/dL; P = .017), higher mean serum creatinine level (1.86 mg/dL vs 1.72 mg/dL; P = .004), and lower mean estimated glomerular filtration rate (55.64 mL/min vs 58.01 mL/min; P = .003) at 1 to 6 months’ follow-up. Compared with the faricimab cohort, the bevacizumab cohort (each n = 3500) showed increased risk of stroke (risk ratio [RR], 1.71, 95% CI, 1.19–2.48), venous thromboembolism (RR, 1.80, 95% CI, 1.11–2.93), myocardial infarction (RR, 1.72, 95% CI, 1.19–2.49), and hypertension (RR, 1.47, 95% CI, 1.19–1.83) within 2 years of follow-up. No significant differences were found between the bevacizumab and ranibizumab cohorts (each n = 2211). Conclusions: Bevacizumab may confer an increased risk of cardiovascular events and differences in renal function parameters compared with aflibercept and faricimab, but not ranibizumab. This underscores the importance of tailoring anti-VEGF therapy to patient-specific profiles, particularly in patients with underlying cardiovascular and renal comorbidities. Further studies in lower-comorbidity populations are needed to clarify these associations.
- 25 September 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Comparative Analysis of Systemic Complications of Antivascular Endothelial Growth Factor Therapies in Retinal Diseases
Purpose: To compare the systemic safety profiles of antivascular endothelial growth factor (anti-VEGF) agents using a large real-world dataset. Methods: The TriNetX Research Network database was used to identify adults with macular edema secondary to diabetes, retinal vein occlusion, or age-related macular degeneration who received bevacizumab, ranibizumab, or aflibercept (2012–2022) or faricimab (2022–2024). The bevacizumab cohort was matched with the other cohorts using propensity score matching to account for demographic characteristics and comorbidities. Outcomes included stroke, venous thromboembolism, myocardial infarction, hypertension, brain hemorrhage, and renal function. Results: In the propensity score–matched cohorts comparing outcomes between bevacizumab and aflibercept (each n = 9538), bevacizumab was associated with higher mean blood urea nitrogen level (28.07 mg/dL vs 26.89 mg/dL; P = .017), higher mean serum creatinine level (1.86 mg/dL vs 1.72 mg/dL; P = .004), and lower mean estimated glomerular filtration rate (55.64 mL/min vs 58.01 mL/min; P = .003) at 1 to 6 months’ follow-up. Compared with the faricimab cohort, the bevacizumab cohort (each n = 3500) showed increased risk of stroke (risk ratio [RR], 1.71, 95% CI, 1.19–2.48), venous thromboembolism (RR, 1.80, 95% CI, 1.11–2.93), myocardial infarction (RR, 1.72, 95% CI, 1.19–2.49), and hypertension (RR, 1.47, 95% CI, 1.19–1.83) within 2 years of follow-up. No significant differences were found between the bevacizumab and ranibizumab cohorts (each n = 2211). Conclusions: Bevacizumab may confer an increased risk of cardiovascular events and differences in renal function parameters compared with aflibercept and faricimab, but not ranibizumab. This underscores the importance of tailoring anti-VEGF therapy to patient-specific profiles, particularly in patients with underlying cardiovascular and renal comorbidities. Further studies in lower-comorbidity populations are needed to clarify these associations.
- 26 May 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (6) , 1292-1298
The Effect of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonists on the Risk of Development and Progression of Age-Related Macular Degeneration
Purpose: To investigate whether memantine or acetylcholinesterase inhibitors are associated with reduced risk of developing age-related macular degeneration (AMD) and of progression from nonexudative to exudative AMD. Methods: This retrospective cohort study used data from the TriNetX US Collaborative Network between 2008 and 2023. Adults 50 years and older were included and categorized into AMD-naïve and dry AMD cohorts. Exposure groups were defined by outpatient prescriptions for acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine. Each exposure group was propensity score–matched 1:1 to unexposed controls based on demographic and clinical characteristics. Outcomes were incident AMD in the AMD-naïve cohort and incident exudative AMD in the dry AMD cohort at least 1 year after the prescription. Risk ratios (RRs) and 95% CIs were estimated, and memantine was compared with acetylcholinesterase inhibitors in a head-to-head analysis. Results: Among AMD-naïve patients, acetylcholinesterase inhibitor use (n = 35 397) and memantine use (n = 13 576) were associated with lower AMD incidence compared with matched controls (RR, 0.490; 95% CI, 0.442–0.543; P < .001; and RR, 0.532; 95% CI, 0.448–0.630; P < .001, respectively). In patients with dry AMD, both acetylcholinesterase inhibitors and memantine were associated with reduced progression to exudative AMD (RR, 0.448; 95% CI, 0.357–0.562; P < .001; and RR, 0.552; 95% CI, 0.362–0.842; P = .005). In head-to-head comparisons, similar risks for incident AMD were seen with memantine and acetylcholinesterase inhibitors (RR, 0.929; 95% CI, 0.762–1.132; P = .46) and progression to exudative AMD (RR, 1.198; 95% CI, 0.720–1.994; P = .49). Conclusions: Memantine and acetylcholinesterase inhibitors were associated with a reduced risk of AMD development and progression. These findings support further investigation into shared neuroprotective pathways and potential drug repurposing.
- 26 May 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (6) , 1292-1298
The Effect of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonists on the Risk of Development and Progression of Age-Related Macular Degeneration
Purpose: To investigate whether memantine or acetylcholinesterase inhibitors are associated with reduced risk of developing age-related macular degeneration (AMD) and of progression from nonexudative to exudative AMD. Methods: This retrospective cohort study used data from the TriNetX US Collaborative Network between 2008 and 2023. Adults 50 years and older were included and categorized into AMD-naïve and dry AMD cohorts. Exposure groups were defined by outpatient prescriptions for acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine. Each exposure group was propensity score–matched 1:1 to unexposed controls based on demographic and clinical characteristics. Outcomes were incident AMD in the AMD-naïve cohort and incident exudative AMD in the dry AMD cohort at least 1 year after the prescription. Risk ratios (RRs) and 95% CIs were estimated, and memantine was compared with acetylcholinesterase inhibitors in a head-to-head analysis. Results: Among AMD-naïve patients, acetylcholinesterase inhibitor use (n = 35 397) and memantine use (n = 13 576) were associated with lower AMD incidence compared with matched controls (RR, 0.490; 95% CI, 0.442–0.543; P < .001; and RR, 0.532; 95% CI, 0.448–0.630; P < .001, respectively). In patients with dry AMD, both acetylcholinesterase inhibitors and memantine were associated with reduced progression to exudative AMD (RR, 0.448; 95% CI, 0.357–0.562; P < .001; and RR, 0.552; 95% CI, 0.362–0.842; P = .005). In head-to-head comparisons, similar risks for incident AMD were seen with memantine and acetylcholinesterase inhibitors (RR, 0.929; 95% CI, 0.762–1.132; P = .46) and progression to exudative AMD (RR, 1.198; 95% CI, 0.720–1.994; P = .49). Conclusions: Memantine and acetylcholinesterase inhibitors were associated with a reduced risk of AMD development and progression. These findings support further investigation into shared neuroprotective pathways and potential drug repurposing.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251794
Nephrogenic Systemic Fibrosis in Patients with Advanced Renal Dysfunction Following Gadolinium-based Contrast Agents
In patients with stage 4 or 5 chronic kidney disease or end-stage renal disease who received gadolinium-based contrast agents since 2010, diagnostic codes for potential nephrogenic systemic fibrosis or mimics were exceedingly rare.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251794
Nephrogenic Systemic Fibrosis in Patients with Advanced Renal Dysfunction Following Gadolinium-based Contrast Agents
In patients with stage 4 or 5 chronic kidney disease or end-stage renal disease who received gadolinium-based contrast agents since 2010, diagnostic codes for potential nephrogenic systemic fibrosis or mimics were exceedingly rare.
- Open Access
- 12 September 2025
- Published by JMIR Publications Inc. in JMIR Biomedical Engineering
- Vol. 10 (1) , e82980
Correction: Can Artificial Intelligence Diagnose Knee Osteoarthritis?
[This corrects the article DOI: 10.2196/67481.].
- 12 September 2025
- Published by JMIR Publications Inc. in JMIR Biomedical Engineering
- Vol. 10 (1) , e82980
Open AccessCorrection: Can Artificial Intelligence Diagnose Knee Osteoarthritis?
[This corrects the article DOI: 10.2196/67481.].
- Open Access
- 25 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Correction: Can Artificial Intelligence Diagnose Knee Osteoarthritis? (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- 25 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCorrection: Can Artificial Intelligence Diagnose Knee Osteoarthritis? (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- Open Access
- 23 April 2025
- Published by JMIR Publications Inc. in JMIR Biomedical Engineering
- Vol. 10, e67481
Can Artificial Intelligence Diagnose Knee Osteoarthritis?
This study analyzed the capability of GPT-4o to properly identify knee osteoarthritis and found that the model had good sensitivity but poor specificity in identifying knee osteoarthritis; patients and clinicians should practice caution when using GPT-4o for image analysis in knee osteoarthritis.
- 23 April 2025
- Published by JMIR Publications Inc. in JMIR Biomedical Engineering
- Vol. 10, e67481
Open AccessCan Artificial Intelligence Diagnose Knee Osteoarthritis?
This study analyzed the capability of GPT-4o to properly identify knee osteoarthritis and found that the model had good sensitivity but poor specificity in identifying knee osteoarthritis; patients and clinicians should practice caution when using GPT-4o for image analysis in knee osteoarthritis.
- Open Access
- 12 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Can Artificial Intelligence Diagnose Knee Osteoarthritis? (Preprint)
UNSTRUCTURED This study analyzed the capability of GPT-4o to properly identify knee osteoarthritis and found that the model had good sensitivity but poor specificity in identifying knee osteoarthritis; patients and clinicians should practice caution when using GPT-4o for image analysis in knee osteoarthritis.
- 12 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCan Artificial Intelligence Diagnose Knee Osteoarthritis? (Preprint)
UNSTRUCTURED This study analyzed the capability of GPT-4o to properly identify knee osteoarthritis and found that the model had good sensitivity but poor specificity in identifying knee osteoarthritis; patients and clinicians should practice caution when using GPT-4o for image analysis in knee osteoarthritis.